ANDA 207479, held by Sciegen Pharms. Bupropion Hydrochloride.
As of Nov 16, 2026, ANDA 207479 (Bupropion Hydrochloride), held by Sciegen Pharms, was first approved by FDA on Apr 12, 2017, with 2 approved supplements and 0 published complete response letters.
Bupropion hydrochloride extended-release tablets (XL) are an aminoketone antidepressant, indicated for: treatment of major depressive disorder (MDD) prevention of seasonal affective disorder (SAD) 1.1 Major Depressive Disorder (MDD) Bupropion hydrochloride extended-release tablets (XL) are indicated for the treatment of major depressive disorder (MDD), as defined by the Diagnostic and Statistical Manual (DSM). The efficacy of the immediate-release formulation of bupropion was established in two 4-week controlled inpatient trials and one 6-week controlled outpatient trial of adult patients with MDD.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 12, 2017 | Original application | Approved | None posted |
| Bupropion Hydrochloride150MG · tablet, extended release;oral | Bupropion Hydrochloride | Rx |
| Bupropion Hydrochloride300MG · tablet, extended release;oral | Bupropion Hydrochloride | Rx |
| Jun 30, 2020 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jun 30, 2020 | Supplement 10Labeling · Standard review | Approved | None posted |
| Apr 12, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters